VANCOUVER, Dec. 8 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) will host its Annual Analyst and Investor meeting on December 9, 2004 at 8:30 a.m. in New York. This is the first time since the merger of QLT and Atrix Laboratories that the company will be presenting the combined product pipeline.
Program highlights include:
- a review of the age-related macular degeneration (AMD) competitive
- market research results for the expected upcoming 6-month Eligard(R)
approval/launch for the treatment of prostate cancer;
- an outline of the market potential for Aczone(TM), recently filed with
the FDA for the treatment of acne;
- preliminary 3- and 6-month results of the lemuteporfin(TM) Phase I/II
program for the treatment of benign prostatic hyperplasia (BPH); and
- an exploration of the potential for the Atrigel(R) sustained release
delivery system, including its potential for intraocular applications.
Presenters include representatives from the Research and Development staff of both the US and Vancouver locations and therefore provides an opportunity to witness the breadth and depth of the combined scientific and clinical management team.
Preliminary results from the Phase I/II lemuteporfin study in BPH were very encouraging and showed not only that the treatment was well tolerated by most patients, but also showed indications of early efficacy with a 3-month improvement in average AUA (American Urological Association) symptom scores in all cohorts. The company plans to continue its development of lemuteporfin in BPH in a Phase IIb study.
Also, while the results of lemuteporfin in androgenetic alopecia showed an increased mean or average hair count, the company will not develop this indication on its own and has prioritized the BPH program.
An audio Webcast will be available live and archived for 30 days, at the QLT Web site at http://www.qltinc.com/.
About QLT Inc.
QLT Inc. is a global biopharmaceutical company specializing in developing treatments for cancer, eye diseases and dermatological and urological conditions.
We have combined our expertise in the discovery, development, commercialization and manufacture of innovative drug therapies with our unique technology platforms to create highly successful products such as Visudyne(R) and Eligard(R).
For more information, visit our website at http://www.qltinc.com/.
Therese Hayes / Tamara Hicks
Telephone: 604-707-7000 or 1-800-663-5486
Visudyne is a registered trademark of Novartis AG.
Eligard is a registered trademark of Sanofi-Aventis.
Aczone is a trademark that has been applied for by Fujisawa Healthcare,
Atrigel is a registered trademark of QLT USA, Inc.
QLT Inc. is listed on The Nasdaq Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."
Certain statements in this press release constitute "forward-looking statements" of QLT within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, the statements that the approval and launch of the 6-month formulation of Eligard is expected and upcoming, the anticipated market potential for Aczone, statements that the company is exploring the potential for the Atrigel sustained release delivery system including its potential for intraocular applications and statements regarding the company's plans for a Phase IIb study of lemuteporfin in BPH. These forward-looking statements are only predictions and actual events or results may differ materially. Factors that could cause actual events or results to differ materially include, but are not limited to: the risk that regulatory approvals for the 6-month formulation of Eligard and/or Aczone may not be obtained, the risk that the company may not successfully develop further products using the Atrigel sustained release delivery system, including in an intraocular application, the risk that our clinical development programs (including studies involving Lemuteporfin in BPH) might not be successful and other risk factors which are described in detail in QLT's Annual Information Form on Form 10-K, quarterly reports on Form 10-Q, Registration Statement on Form S-4 and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on our current expectations and QLT does not assume any obligation to update such information to reflect later events or developments, except as may be required by law.